Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia - Wikidata - wikimedia - TriplyDB

Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia

Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia

http://www.wikidata.org/entity/Q34973729

about

Investigational drugs to treat methicillin-resistant Staphylococcus aureus Where does a Staphylococcus aureus vaccine stand?A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America Progress towards recombinant anti-infective antibodies.Inhibition of toxic shock by human monoclonal antibodies against staphylococcal enterotoxin B.Novel targeted immunotherapy approaches for staphylococcal infection.Preventing Staphylococcus aureus sepsis through the inhibition of its agglutination in blood.Progress in the development of effective vaccines to prevent selected gram-positive bacterial infections.Applying Convergent Immunity to Innovative Vaccines Targeting Staphylococcus aureus.Passive immunization with anti-glucosaminidase monoclonal antibodies protects mice from implant-associated osteomyelitis by mediating opsonophagocytosis of Staphylococcus aureus megaclusters.Vaccine protection of leukopenic mice against Staphylococcus aureus bloodstream infection Mechanisms of NDV-3 vaccine efficacy in MRSA skin versus invasive infection.Protein A suppresses immune responses during Staphylococcus aureus bloodstream infection in guinea pigs.Active immunization with an octa-valent Staphylococcus aureus antigen mixture in models of S. aureus bacteremia and skin infection in mice An evaluation of the emerging vaccines and immunotherapy against staphylococcal pneumonia in children.Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance?Immunization with Staphylococcus aureus iron regulated surface determinant B (IsdB) confers protection via Th17/IL17 pathway in a murine sepsis model Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia Innate Immune Signaling Activated by MDR Bacteria in the Airway Epidemiology and outcome of major postoperative infections following cardiac surgery: risk factors and impact of pathogen type.Exploring Staphylococcus aureus pathways to disease for vaccine development.Preclinical Efficacy of Clumping Factor A in Prevention of Staphylococcus aureus Infection.Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections.Immunopathogenesis of Staphylococcus aureus pulmonary infection.Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.Treatment of Staphylococcus aureus infections: new issues, emerging therapies and future directions.Global antibody response to Staphylococcus aureus live-cell vaccination Monoclonal antibodies for prophylaxis and therapy of infectious diseases.Targeting Alpha Toxin and ClfA with a Multimechanistic Monoclonal-Antibody-Based Approach for Prophylaxis of Serious Staphylococcus aureus Disease Management of catheter-related infection.Successful selection of an infection-protective anti-Staphylococcus aureus monoclonal antibody and its protective activity in murine infection models Lessons from the Crystal Structure of the S. aureus Surface Protein Clumping Factor A in Complex With Tefibazumab, an Inhibiting Monoclonal Antibody.Invasive community-associated MRSA infections: epidemiology and antimicrobial management.Immune proteomics of Staphylococcus aureus.Advances in the diagnosis and management of pediatric osteomyelitis.Diabetic foot infections: microbiological aspects, current and future antibiotic therapy focusing on methicillin-resistant Staphylococcus aureus.Challenges for a universal Staphylococcus aureus vaccine.Staphylococcus aureus Colonization: Modulation of Host Immune Response and Impact on Human Vaccine Design.Multimechanistic Monoclonal Antibodies (MAbs) Targeting Staphylococcus aureus Alpha-Toxin and Clumping Factor A: Activity and Efficacy Comparisons of a MAb Combination and an Engineered Bispecific Antibody Approach.

P2860

Q26780246-E4A135D1-9D93-461C-86B6-31F9650D5A9E Q26828726-0D446D8D-E053-4A6A-B7BA-4E53A2E3F007 Q28714292-28C9BD4F-45DB-4CF6-B933-5B16CBA00F1E Q29616084-D96D6343-E850-4D02-90A5-B4FE10050E23 Q33568256-05348C40-9D4E-43CF-BD4B-CF0B7691E9FA Q33719201-43DAEDEA-4C55-4C7B-8310-F4546EB2BC4D Q33910565-BC3C79F2-C286-462D-A665-59D1A110021D Q34058113-43F45BBF-B2A3-4DD5-9A8B-C94B0815B06B Q34112608-511BFBEF-6186-4B5B-9E58-F515176185B6 Q34250054-141B011E-7302-43BF-9A5C-9A2A42C8BAC4 Q34522708-AAA3D2B7-BB6B-4B3E-A4CC-D00C506B5CE1 Q34596203-EBF80962-1378-446B-BBFB-6D8ED6BB420B Q34792962-38B65B52-92D5-4EE7-B5C7-8B73D6F061A2 Q35038206-200DF2E3-4913-487D-B80D-1EB33A7F008C Q35116935-34B31A26-4BF1-45A3-8018-2D9361B7A2CF Q35618211-E1F848E4-C346-4876-8400-9D792BE28FC1 Q35736907-0D76ACD4-B030-4B83-B695-9068FED42AC5 Q36184397-A0114F73-84C3-4781-B5B7-BAF18251FFE7 Q36313264-1C0E9929-6BE1-4C56-A35F-50D934E14706 Q36422470-FDE80008-5261-4C6A-B329-7EB21DE8ECD2 Q36503755-A7604E63-2BE2-4669-AC4B-F6AC6AF701DF Q36516970-E798BC71-17AA-4959-BB58-27092C33ECC4 Q36548288-9DEEB676-C3BB-46E5-9EF2-240E8B8E15B9 Q36609408-4AD40EF3-9A9C-4405-ADF1-3F4E5D01E5F3 Q36623309-17397870-CFBF-46E3-8C98-4607BA5A9881 Q36718474-7FB36D0F-1E65-4364-AD72-1FB5E2C94451 Q36758570-9AE407FB-ED8F-4914-A2F7-C1ED35E08BE1 Q36824281-ACD422A0-EE3B-4A87-A1C7-93CEB28B359F Q36989900-F6704649-D8CF-44E2-8811-3F4F05F98566 Q37075941-E5642319-F5ED-4F4A-A6C7-4FD0645D6B90 Q37077615-D5FEF23E-1A3C-4CF2-9575-B3976473B78B Q37269558-5B28BDA5-B916-4982-B1F1-D5912291E09E Q37605209-36D34F96-8254-48B1-829D-2F1F3EFA67F5 Q37800939-6B069B02-9500-4617-851D-DB498A1DAF9F Q37895214-6F16DD54-7417-4DE3-B59F-AB82687820A0 Q37905654-BFBEF949-B7C8-471A-8E84-CE792EA9F447 Q37924980-04B27C2F-6220-4483-9788-9DDD9F3E21C4 Q37987099-A9564BA2-4663-456E-A4D5-D2D7D4D2E974 Q38177271-5B1DAA2F-EEAE-4F56-8A63-CB170023F2F2 Q38674449-6E9C355F-3CB9-417E-95D8-66C5FC65CC59

P2860

Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia

http://www.wikidata.org/entity/Q34973729

description

2006 nî lūn-bûn

@nan

2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

name

Phase II, randomized, double-b ...... aphylococcus aureus bacteremia

@ast

Phase II, randomized, double-b ...... aphylococcus aureus bacteremia

@en

Phase II, randomized, double-b ...... aphylococcus aureus bacteremia

@nl

type

label

Phase II, randomized, double-b ...... aphylococcus aureus bacteremia

@ast

Phase II, randomized, double-b ...... aphylococcus aureus bacteremia

@en

Phase II, randomized, double-b ...... aphylococcus aureus bacteremia

@nl

prefLabel

Phase II, randomized, double-b ...... aphylococcus aureus bacteremia

@ast

Phase II, randomized, double-b ...... aphylococcus aureus bacteremia

@en

Phase II, randomized, double-b ...... aphylococcus aureus bacteremia

@nl

P1433

Q34973729-2EBEB426-2DC7-4BAD-9A06-389F2F073C8F

P1476

Q34973729-96172AD0-666E-4BEE-814D-4F7B3BFC984A

P2093

Q34973729-14C2AB31-70B7-43C4-910C-660D6FEE7139

Q34973729-36FFCF74-85BD-403F-90E8-86968EB0EBBB

Q34973729-4075F6E0-3248-4FF2-8EEC-D45B246BCC1A

Q34973729-45997B93-6D76-4235-82E0-FBDC8A3A5CB4

Q34973729-56E2082E-3D36-4620-8758-53A4AA5AF956

Q34973729-67ABE12B-25A4-472C-B3AD-CF64D9DD5E6B

Q34973729-68472467-053E-48AE-AB20-8F0694F38B8C

Q34973729-6C5414A1-0104-4929-A91C-D7C85CFD5293

Q34973729-75C844F1-8339-4B12-B1EE-1B126B0A22A2

Q34973729-77064532-CE0B-465C-8175-899DCBEBBD11

P2860

Q34973729-0E6BD033-195A-4E11-8324-1530A5C9DC15

Q34973729-0E91E018-ACAC-48A5-9A0C-0A64086974E6

Q34973729-1CB985BA-9912-4203-888F-215F50AF192F

Q34973729-2E47A432-24AC-4AA0-8033-9FC06968E490

Q34973729-30C7597F-20BA-4585-A9D5-7489B5805B78

Q34973729-3486E5D2-65E5-4687-B02E-DF5A7F00A8B3

Q34973729-35FD0D0E-C89F-4CEB-B01B-EC67816EE4E4

Q34973729-409499B8-3FE8-41B2-9D59-2E356AC5AAF9

Q34973729-4FCEAE26-2FCF-4859-ACC9-7362378A2342

Q34973729-57974A26-A8E6-4A26-AE38-6A7A2489834F

P304

Q34973729-7A94D6C7-1FC5-4E77-9E6B-C282646672AD

P31

Q34973729-E23630C1-7171-4F39-899E-DF14DBFC3447

P356

Q34973729-A51407D2-03B2-4D74-8FD0-A952B8E5E0ED

P407

Q34973729-AE545BDE-5F7B-4F4C-979D-ACB5C9E42982

P433

Q34973729-481D42FD-836D-4665-B071-0C76C3BEAB73

P478

Q34973729-1E517FE0-13E4-463C-8DF7-E76C9E67F4D5

P50

Q34973729-5F01C441-4E88-42E5-A0A9-5C71F058E57E

Q34973729-DB38374A-142D-41B1-977D-4132FBBD0BE8

P577

Q34973729-F7D3050B-A6FC-415A-9ADA-F262FAB3ACB1

P5875

Q34973729-FCE4813E-078E-4B50-842E-965A3AC8647F

P698

Q34973729-EFFD7396-7B2D-4057-98C4-5F7EF82CEBCF

P921

Q34973729-27C175C3-9FA5-4B58-B619-CAC2B608CABA

Q34973729-D3188D5B-CFCE-48CC-B7CB-1B0713743794

P932

Q34973729-F59B1047-632E-44A0-A44D-3CDA7127C0E9

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Phase II, randomized, double-b ...... aphylococcus aureus bacteremia

@en

P2093

Christine J Kubin

http://www.w3.org/2001/XMLSchema#string

Eric Wenzel

http://www.w3.org/2001/XMLSchema#string

G Ralph Corey

http://www.w3.org/2001/XMLSchema#string

J John Weems

http://www.w3.org/2001/XMLSchema#string

James P Steinberg

http://www.w3.org/2001/XMLSchema#string

John W Baddley

http://www.w3.org/2001/XMLSchema#string

Joseph F John

http://www.w3.org/2001/XMLSchema#string

Joseph M Patti

http://www.w3.org/2001/XMLSchema#string

Lisa Winston

http://www.w3.org/2001/XMLSchema#string

Michele Texter

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

Staphylococcus aureus infections

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference

Open-label, dose escalation study of the safety and pharmacokinetic profile of tefibazumab in healthy volunteers.

Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis.

Characterization of a humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus.

Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study.

The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database.

Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A.

P304

2751-2755

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00096-06

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6915217

http://www.w3.org/2001/XMLSchema#string

P698

16870768

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

1538656

http://www.w3.org/2001/XMLSchema#string